The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

Abstract Patients with epidermal growth factor receptor (EGFR) exon 21 L858R substitution benefit less from standard EGFR tyrosine kinase inhibitor (TKI) treatment, and whether anti-angiogenic therapy was beneficial to the EGFR L858R subpopulation was inconclusive. A retrospective study was conducte...

Full description

Bibliographic Details
Main Authors:	Liangkun You, Xinnan Zheng, Danchen Deng, Hongming Pan, Weidong Han
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-08-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-022-18889-z

Similar Items

Survival Analysis of Lung Adenocarcinoma Patients with Exon 19 Del and 21 L858R Mutations Receiving EGFR-TKI Treatment
by: Stephen Johan Prasetyo, et al.
Published: (2023-05-01)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
by: Kumar Prabhash, et al.
Published: (2023-12-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
by: Meiyi XU, et al.
Published: (2023-02-01)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
by: Pacini L, et al.
Published: (2021-03-01)

Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
by: Francesca Foschi, et al.
Published: (2023-12-01)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFRWT, EGFRT790M, and EGFRL858R)
by: Mahmoud G. Abo Al-Hamd, et al.
Published: (2023-12-01)

Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas
by: Daisuke Akahori, et al.
Published: (2021-07-01)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
by: Timothée Olivier, et al.
Published: (2022-09-01)

Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis
by: Zan-Feng Wang, et al.
Published: (2018-02-01)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
by: Geunho Choi, et al.
Published: (2021-07-01)

Clinical Characteristics and Outcomes of Lung Cancer Patients  with EGFR Mutations in Exons 19 and 21
by: Renwang LIU, et al.
Published: (2014-11-01)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
by: Jiang-Yong Yu, et al.
Published: (2016-03-01)

Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations
by: Michihiro Kunishige, et al.
Published: (2023-12-01)

Prevalence, Treatment Patterns, and Outcomes of Individuals with <i>EGFR</i> Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion <i>EGFR</i> Mutation Carriers
by: Dylan E. O’Sullivan, et al.
Published: (2022-09-01)

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
by: Wang L, et al.
Published: (2023-10-01)

Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients
by: Liang H, et al.
Published: (2020-09-01)

First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient  with EGFR Exon 20 Insertion Mutantion
by: Zhengguo LI, et al.
Published: (2024-03-01)

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
by: Toshihiko Kaneda, et al.
Published: (2018-01-01)

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
by: Naoya Ishibashi, et al.
Published: (2023-12-01)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021-03-01)

Determinación de mutaciones (del E746-A750 exón 19 y L858R exón 21) en el gen receptor del factor de crecimiento epidérmico (EGFR) en muestras de suero y biopsia de carcinoma pulmonar no microcítico (CPNM)
by: Karla Castro-Valencia, et al.
Published: (2018-09-01)

Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review
by: Qianqian Zhang, et al.
Published: (2022-05-01)

Unusual metachronous lung adenocarcinomas harboring EGFR L858R/T790M mutations: A case report
by: Guotian Pei, et al.
Published: (2020-10-01)

Curative Effect of EGFR-TKIs with Anti-angiogenic Drugs as the Treatment for Patients with Advanced EGFR-mutant Non-small Cell Lung Cancer：a Meta-analysis
by: LI Yong, LONG Yong, ZHAO Chong, ZHANG Guanqing, SU Yanhe
Published: (2022-03-01)

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
by: Chien-Hung Gow, et al.
Published: (2005-09-01)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
by: Ikei S. Kobayashi, et al.
Published: (2021-12-01)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
by: Guangrui Li, et al.
Published: (2023-10-01)

Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib
by: Michihiro Kunishige, et al.
Published: (2023-02-01)

Selective Targeting of the L858R Mutation (EGFR) in Non-Small Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy
by: Rohan Arora, et al.
Published: (2017-05-01)

Simultaneous Detection of the T790M and L858R Mutations in the <i>EGFR</i> Gene by Oligoribonucleotide Interference-PCR
by: Keisuke Baba, et al.
Published: (2019-08-01)

Retrospective study of EGFR‐mutant lung adenocarcinoma with bone metastatic clinical features
by: Liyan Gu, et al.
Published: (2023-01-01)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
by: Takumi Fujiwara, et al.
Published: (2020-10-01)

Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
by: Yaxiong Zhang, et al.
Published: (2014-01-01)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
by: Huamao M. Lin, PhD, et al.
Published: (2022-03-01)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
by: Lingzhi Hong, et al.
Published: (2022-07-01)

Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
by: Sik-Kwan Chan, PhD, et al.
Published: (2022-05-01)

Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations
by: Jiaqi Li, et al.
Published: (2024-03-01)

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature
by: Chukwuka Eze, et al.
Published: (2017-05-01)

Aumolertinib: effective treatment for asymptomatic pulmonary giant cell carcinoma with EGFR L858R mutation - a case report
by: Wenxing Yang, et al.
Published: (2023-11-01)

Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report
by: Wei Jing, et al.
Published: (2020-05-01)